The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Believe it or not: how much can we rely on published data on potential drug targets?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“reports from the pharmaceutical industry (Begley & Ellis, 2012;Prinz et al., 2011) and systematic assessments of replicability in specific fields, such as cancer biology (Errington, Mathur, et al., 2021), spinal cord injury (Steward et al., 2012) and amyotrophic lateral sclerosis (Scott et al., 2008), have reported success rates ranging from 0 to 40%.”
From Estimating the replicability of Brazilian biomedical science (2025) · cites this paper as Prinz et al., 2011
In the citing paper
“These numbers are in a similar range as previous estimates from the biomedical literature (Begley & Ellis, 2012;Errington, Mathur, et al., 2021;Prinz et al., 2011;Scott et al., 2008;Steward et al., 2012).”
From Estimating the replicability of Brazilian biomedical science (2025) · cites this paper as Prinz et al., 2011
In the citing paper
“This may contribute to publication bias, selective reporting, and questionable research practices that reduce the credibility of the published literature 18-25 .”
From Initial evidence of research quality of registered reports compared with the standard publishing model (2021) · cites this paper as [19]
In the citing paper
“Scientists at Bayer have reported that only ~25% of published preclinical studies could be validated to the point at which projects could progress.2”
From Reproducibility of Quantitative Systems Pharmacology Models: Current Challenges and Future Opportunities (2019) · cites this paper as [2]
In the citing paper
“A team at Bayer HealthCare in Germany last year reported 4 that only about 25% of published preclinical studies could be validated to the point at which projects could continue.”
From Raise standards for preclinical cancer research (2012) · cites this paper as [4]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2019) · CHANCE · doi:10.1080/09332480.2019.1579573 · Cited by 463
What errors do peer reviewers detect, and does training improve their ability to detect them?
Schroter, S., Black, N., Evans, S., Godlee, F., Osorio, L., & Smith, R. (2008) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2008.080062 · Cited by 226
Osherovich, L. Z. (2011) · Science-Business eXchange · doi:10.1038/scibx.2011.416 · Cited by 43
Factors Affecting Reproducibility between Genome-Scale siRNA-Based Screens
Barrows, N. J., Sommer, C., García-Blanco, M. A., & Pearson, J. L. (2010) · SLAS DISCOVERY · doi:10.1177/1087057110374994 · Cited by 39
McDonald, R. J., Cloft, H. J., & Kallmes, D. F. (2007) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0766 · Cited by 31
Nemery, B. (2001) · Occupational and Environmental Medicine · doi:10.1136/oem.58.9.604 · Cited by 23 · cited 1×
“Adding to this problem, many initially rejected papers will subsequently be published in other journals without substantial changes or improvement”
Background
Research works printed but not linked: 2
- Lehrer, J. The truth wears off: is there something wrong with the scientific method? The New Yorker [online], (2010).
- Freeman, D. H. Lies, damned lies, and medical science. The Atlantic [online], (2010).
Cited by
Estimating the reproducibility of psychological science
Open Science Collaboration (2015) · Science · doi:10.1126/science.aac4716 · Cited by 8,515
Radiomics: Images Are More than Pictures, They Are Data
Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016) · Radiology · doi:10.1148/radiol.2015151169 · Cited by 8,421
Power failure: why small sample size undermines the reliability of neuroscience
Button, K. S., Ioannidis, J. P. A., Mokrysz, C., Nosek, B. A., Flint, J., Robinson, E. S. J., & Munafò, M. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3475 · Cited by 7,641
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Increasing value and reducing waste in research design, conduct, and analysis
Ioannidis, J. P. A., Greenland, S., Hlatky, M. A., Khoury, M. J., Macleod, M. R., Moher, D., Schulz, K. F., & Tibshirani, R. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62227-8 · Cited by 1,597
Metadata
- Authors
- Prinz, F., Schlange, T., & Asadullah, K.
- Affiliations
- Bayer (Germany) (DE)
- Corresponding author
- Asadullah, Khusru
- ORCID
- Schlange, Thomas
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-31
- Volume
- 10
- Issue
- 9
- Pages
- 712-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2067833766
- Cited by
- 1,888
- References
- 8
- Citations by year
- 2026: 56 · 2025: 60 · 2024: 86 · 2023: 108 · 2022: 138 · 2021: 126 · 2020: 131 · 2019: 171 · 2018: 147 · 2017: 176 · 2016: 202 · 2015: 183 · 2014: 141 · 2013: 98 · 2012: 57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- therapeutic target, reproducibility, publication bias, false positives, peer review, manuscript rejection, siRNA screen, drug target validation
- MeSH terms
- Drug Industry, Humans, Drug Design, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Believe it or not: how much can we rely on published data on potential drug targets? https://app.cochat.ai/papers/10.1038/nrd3439-c1
- The paper
- Prinz, F., Schlange, T., & Asadullah, K. (2011). Believe it or not: how much can we rely on published data on potential drug targets? Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd3439-c1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.